Last $2.46 USD
Change Today +0.10 / 4.24%
Volume 149.7K
NSPR On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

inspiremd inc (NSPR) Snapshot

Open
$2.41
Previous Close
$2.36
Day High
$2.63
Day Low
$2.41
52 Week High
02/26/14 - $3.80
52 Week Low
08/27/13 - $1.80
Market Cap
88.4M
Average Volume 10 Days
245.1K
EPS TTM
$-1.03
Shares Outstanding
35.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INSPIREMD INC (NSPR)

Related News

No related news articles were found.

inspiremd inc (NSPR) Related Businessweek News

No Related Businessweek News Found

inspiremd inc (NSPR) Details

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MGuard stent platform technology. Its MGuard stent is an embolic protection device based on a protective sleeve, which is constructed out of an ultra-thin polymer mesh and wrapped around the stent. The company markets its products for use primarily in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack), and saphenous vein graft coronary interventions (bypass surgery). It serves various customers in Europe, Latin America, Asia, Israel, and internationally. InspireMD, Inc. is headquartered in Boston, Massachusetts.

71 Employees
Last Reported Date: 02/26/14

inspiremd inc (NSPR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $142.3K
Chief Technology Officer, Chief Technical Off...
Total Annual Compensation: $136.3K
Compensation as of Fiscal Year 2013.

inspiremd inc (NSPR) Key Developments

InspireMD, Inc. Announces Enrollment of First Patient into New CGuard(TM) CARotid Embolic Protection Study Using microNET Clinical Trial

InspireMD, Inc. announced that it has successfully enrolled the first patient into the CARENET (CARotid Embolic protection study using microNET) multi-center European clinical trial for the new CGuard(TM) carotid embolic protection system. The CARENET clinical study is a multi-specialty trial that is designed to provide data and evidence of the CGuard carotid embolic protection system to better understand the complexities and challenges of patients that experience carotid artery disease. The objective of the CARENET study is to evaluate the safety and efficacy of the CGuard system in the treatment of carotid lesions in consecutive patients suitable for carotid artery stenting (CAS). The proprietary CGuard carotid embolic protection system uses the same MicroNet(TM) technology featured on the MGuard(TM) and MGuard Prime(TM) coronary embolic protection systems. The MicroNet technology is a single fiber knitted mesh wrapped on an open cell stent platform designed to trap debris that can travel downstream after a patient is treated with traditional stenting methods. This technology seeks to protect patients from plaque debris and blood clots breaking off and traveling distally in the arteries which can lead to life threatening strokes. The size, or aperture, of the MicroNet 'pore' is only 150-180 microns in order to maximize protection against the potentially dangerous plaque and thrombus which is liberated during the procedure. Initiating the CARENET trial ahead of schedule is important for the Company and is indicative of the tremendous clinical interest about the potential benefits of the MicroNet technology in this complex setting.

InspireMD, Inc. Announces Consolidated Financial Results for the Second Quarter and Six Months Ended December 31, 2013

InspireMD, Inc. announced consolidated financial results for the second quarter and six months ended December 31, 2013. For the quarter, revenues were $1,554,000 against $1,350,000 for the same period of last year. Loss from operations was $4,941,000 against $4,366,000 for the same period of last year. Loss before tax expenses was $5,383,000 against $1,878,000 for the same period of last year. Net loss was $5,390,000 against $1,920,000 for the same period of last year. Basic and diluted EPS was $0.16 against $0.11 for the same period of last year. Non-gaap net loss was $4,548,000 or $0.13 per share against $3,122,000 or $0.18 per share for the same period in the last year. For the six months, revenues were $3,105,000 against $1,859,000 for the same period of last year. Loss from operations was $8,827,000 against $7,647,000 for the same period of last year. Loss before tax expenses was $9,326,000 against $9,377,000 for the same period of last year. Net loss was $9,336,000 against $9,426,000 for the same period of last year. Basic and diluted EPS was $0.27 against $0.54 for the same period of last year. Non-gaap net loss was $7,555,000 or $0.22 per share against $5,720,000 or $0.33 per share for the same period in the last year.

InspireMD, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 05:00 PM

InspireMD, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 05:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Alan W. Milinazzo, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSPR:US $2.46 USD +0.10

NSPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardica Inc $0.90 USD +0.005
Cytori Therapeutics Inc $2.34 USD -0.01
Stentys €9.93 EUR +0.08
Uroplasty Inc $3.37 USD +0.11
Vision Sciences Inc/DE $1.08 USD +0.02
View Industry Companies
 

Industry Analysis

NSPR

Industry Average

Valuation NSPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.5x
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSPIREMD INC, please visit www.inspire-md.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.